Posts by Sandra Ansanay-Alex
CleantechAlps Celebrates 15 Years of Accelerating Sustainability Innovation in Western Switzerland
CleantechAlps, the regional hub for clean technologies in Western Switzerland, is marking 15 years of dedicated support to sustainability and cleantech innovation. Launched in 2010 by the cantons of Western Switzerland, the platform has become a strategic catalyst for collaboration, promotion, and development across the cleantech ecosystem in Switzerland and Europe. From its inception,…
Read MoreParkinson’s Disease: How the First Affected Side Shapes the Course of Symptoms
New research from the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) reveals that the side of the body where Parkinson’s disease first manifests plays a critical role in the development of non-motor symptoms such as cognitive decline, anxiety, and depression. Parkinson’s disease, which affects over 10 million people globally, typically begins asymmetrically—impacting…
Read MoreLara Chavaz from HUG Wins Swiss Childhood Cancer Research Award
The official award ceremony for the Swiss Childhood Cancer Research Prize took place in Bern on 18 June 2025, recognizing Lara Chavaz of the Geneva University Hospitals (HUG) for her outstanding contribution to pediatric oncology research. The CHF 35,000 prize honors innovative projects in basic research conducted at Swiss research institutes and hospitals. …
Read MoreUNIL Scientists Develop Innovative Method to Reverse Cellular Aging
A team of researchers at the University of Lausanne (UNIL) has unveiled a groundbreaking approach to combat cellular aging using a non-genetic, chemical-based method. Published in EMBO Molecular Medicine, their study demonstrates how a short treatment with a specific combination of small molecules can rejuvenate aged human cells and extend lifespan in microscopic worms, opening…
Read MoreComphya Closes Oversubscribed CHF 7.5 Million Series A Round
Comphya SA, a Vaud-based clinical-stage MedTech company pioneering the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, announced the closing of an oversubscribed Series A financing round. Including the conversion of existing convertible loans, the round brings Comphya’s total equity raised to CHF 7.5 million (~USD 8.4 million). “We are…
Read MoreHilo by Aktiia Received FDA 510(k) Clearance for its Blood Pressure Monitor Wristband
The CSEM spinoff Aktiia has received FDA 510(k) clearance for its over-the-counter cuffless blood pressure monitor, G0 Blood Pressure Monitoring System, also known as the Hilo Band. Thi wearable uses an optical sensor to collect data from one’s wrist. The Hilo by Aktiia wrist wearable is one of a kind as it collects one’s blood…
Read MoreVenture Leaders Medtech Presents the 2025 Cohort
Ten promising startups have been named to the Swiss National Medtech Team 2025 and will travel to Boston from 28 September to 3 October to pitch to investors, expand their network, and meet industry leaders. The Venture Leaders Medtech programme is organized by Venturelab, with the support of EPFL, ETH Zurich, Hansjörg Wyss, Helbling…
Read MoreThe Medtech Forum
The Medtech Forum 2026 is taking place from 13 to 15 May in Lisbon, Portugal The MedTech Forum is the largest health and medical technology industry conference in Europe and a key event since 2007. Industry leaders, leading innovators and investors to discuss the future opportunities in the medical technology sector. The 2025 programme…
Read MoreMBA in Biotech Management
The Geneva Business School launches next fall a MBA in Biotech Management at Campus Biotech Geneva. This MBA equips students with both scientific fluency and strategic business acumen. In a rapidly evolving industry where scientific breakthroughs must translate into real-world impact, the need for visionary leadership has never been greater. The MBA in Biotech…
Read MoreStalicla Secures CHF 2 Million Financing Led by Addex Therapeutics
STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C and the partnering of key programs.…
Read More